All the news Showing 10 of 72 articles from: HCV and coinfectionsGet an RSS feed of these articles Show All news infohep newsEditors' picks from other sources Improvements in HIV treatment and care have had no impact on rates of endstage liver disease among HIV-positive people with viral hepatitis Michael Carter / 01 September 2016 Incidence of endstage liver disease (ESLD) among HIV-positive people with viral hepatitis changed little between 1996 and 2010, despite major improvements in HIV treatment and care, investigators from Canada and the United States ... Statins reduce risk of progression to cirrhosis in people with HIV/HCV co-infection Michael Carter / 30 August 2016 Treatment with statins decreases the risk of progression to liver cirrhosis in people with HIV/hepatitis C virus (HCV) co-infection, investigators from the United States report in AIDS. The protective effect of statins was ... HIV not a risk factor for fibrosis progression in people with hepatitis C Michael Carter / 24 August 2016 HIV co-infection is not associated with accelerated progression of liver fibrosis in people with hepatitis C virus (HCV) infection, according to US research published in the online edition of the Journal of Infectious Diseases. ... Sofosbuvir/velpatasvir shows high cure rate in HIV/HCV co-infection study Liz Highleyman / 21 July 2016 The once-daily co-formulation of sofosbuvir and velpatasvir was highly effective against all hepatitis C virus (HCV) genotypes in people with HIV/HCV co-infection and was safe and well tolerated in the ASTRAL-5 trial, according ... Does having HIV affect response to hepatitis C treatment? Liz Highleyman / 16 May 2016 A study from the US Veterans Health Administration found that HIV-positive people responded as well as those without HIV to direct-acting antiviral (DAA) therapy for hepatitis C, while a Spanish study showed that ... Sofosbuvir/velpatasvir cures HCV in 95% of people with HCV and HIV co-infection Liz Highleyman / 19 April 2016 A dual regimen of sofosbuvir plus velpatasvir was well tolerated and highly effective against hepatitis C virus (HCV) genotypes 1 through 4 in HIV-positive people with chronic hepatitis C co-infection, according to results ... High incidence of HCV reinfection among HIV-positive MSM in Western Europe Michael Carter / 19 April 2016 There is a very high incidence of hepatitis C virus (HCV) reinfection among HIV-positive men who have sex with men (MSM) in western Europe, according to research presented to the International Liver Congress ... Starting HIV therapy associated with improvements in liver function, especially when viral load is suppressed Michael Carter / 21 March 2016 Starting antiretroviral therapy is associated with improvements in liver function in HIV-positive men with and without viral hepatitis co-infection, investigators from the United States report in the online edition of the Journal of ... Sofosbuvir/velpatasvir for hepatitis C can be administered with most antiretrovirals Liz Highleyman / 11 March 2016 Sofosbuvir/velpatasvir, a forthcoming combination that effectively treats all hepatitis C virus (HCV) genotypes, can be safely used with most boosted antiretrovirals for people with HIV and HCV co-infection, according to a study presented ... Sofosbuvir plus ribavirin shows suboptimal efficacy for acute hepatitis C Liz Highleyman / 25 February 2016 A combination of sofosbuvir (Sovaldi) and ribavirin cured more than 90% of hepatitis C in people living with HIV and acute hepatitis C virus (HCV) infection in a small study, but a similar ... ← Prev1...23456...8Next → Other pages in this section Latest news All the news Hepatitis A Hepatitis B Hepatitis C Transmission and prevention Diagnosis and monitoring Disease course and symptoms HCV and coinfections Living with HCV Treatment issues Side effects Therapies Liver transplants Hepatitis D Hepatitis E Coronavirus NAFLD Treatment for hepatocellular carcinoma Transmission, epidemiology and prevention Health services, policy and advocacy Social issues Conference news Email bulletin archive